SCHEMBL2762010

SCHEMBL2762010

COC(=O)c1c(O)c2cc(OCc3ccccc3)ccc2oc1=O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.58
PKM P14618 1/20 0.58
CASP3 P42574 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57
MAOB P27338 5/20 0.53
ACHE P22303 1/20 0.53
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
TSHR P16473 1/20 0.51
SLC16A3 O15427 1/20 0.50
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MAOA P21397 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
RECQL P46063 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762426 0.92 ANO1 (0.50) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL2761681 0.91 MAOB (0.62) CASP3SENP8SENP7SENP6MAOB
SCHEMBL9434162 0.85 CASP3 (0.58) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL2761688 0.84 L3MBTL1 (0.52) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL2783458 0.83 L3MBTL1 (0.51) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL2761639 0.80 MAOB (0.60) MAOBLMNAMAPTTSHRKDM4E
SCHEMBL2761878 0.79 NQO1 (0.49) L3MBTL1MAOBLMNAMAPTTSHR
SCHEMBL2761875 0.79 ALDH1A1 (0.46) L3MBTL1MAOBACHEMAPTKDM4E
SCHEMBL11848560 0.78 PKM (0.52) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL2470943 0.78 EDNRA (0.51) L3MBTL1PKMCASP3SENP8SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 L3MBTL1 3898/4885PKM 814/4885CASP3 2668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.